Venetoclax maintenance for older adults with AML in remission
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether “maintenance” treatment with venetoclax can help older adults with acute myeloid leukemia (AML) stay in remission after initial therapy. It may help delay the return of AML, especially in people who achieved first complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML and it was diagnosed by bone marrow testing and immunophenotyping
- You are in your first remission: CR or CRi after 1–2 induction cycles, and you had consolidation treatment for at least 4 cycles
- Your age is 60 to 85
- Your liver and kidney blood tests are within set limits, and your bilirubin is not too high
- Your heart function is good enough (left ventricular ejection fraction at least 50%), and your physical functioning score is 0–3
- You can sign informed consent, and you are not allergic to any study medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.